DYAI vs BEAM vs TWST vs MRNA

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Analysts rate Beam Therapeutics Inc. (BEAM) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -49.

9%, compared to -82. 1% for Dyadic International, Inc. (DYAI). Over 10 years, the gap is even starker: TWST returned +318. 1% versus DYAI's -56. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Dyadic International, Inc.

(DYAI) is the lower-risk stock at 0. 98β versus Twist Bioscience Corporation's 2. 47β — meaning TWST is approximately 152% more volatile than DYAI relative to the S&P 500. On balance sheet safety, Moderna, Inc. (MRNA) carries a lower debt/equity ratio of 22% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 16. 7% for Dyadic International, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Twist Bioscience Corporation (TWST) is the more profitable company, earning -20.

6% net margin versus -166. 2% for Dyadic International, Inc. — meaning it keeps -20. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TWST leads at -36. 2% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Dyadic International, Inc.

(DYAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DYAI: -56. 4%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DYAI is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; TWST is a small-cap high-growth stock; MRNA is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.